Oritavancin is in the final stages of clinical development for treatment of acute bacterial skin and skin structure infections. This drug has demonstrated potent activity against staphylococci (minimum inhibitory concentration [MIC] for which 90% of isolates are inhibited [MIC 90 ], 0.06 mg/mL), enterococci (MIC 90 , £0.008 to 0.5 mg/mL), and streptococci (MIC 90 , £0.008 to 0.12 mg/mL), including enhanced potency against vancomycin-resistant enterococci. During the clinical development of oritavancin, it was demonstrated that this molecule binds to plastic labware surfaces and that this feature was likely responsible for interlaboratory variability observed from in vitro investigations before 2006. Therefore, reference broth microdilution methods and MIC ranges for quality control strains were reestablished using media supplemented with a surfactant (polysorbate-80, 0.002%). These were followed by numerous experiments to reassess the in vitro characteristics of oritavancin; the results originating from those studies are summarized here. The oritavancin activity tested against a resistance surveillance collection of 12 367 Gram-positive clinical pathogens and resistant subsets from the United States (2008States ( -2009) is also presented, with the highest MIC among staphylococci at only 0.25 mg/mL. In vitro results for oritavancin indicate wide potential use against Gram-positive pathogens.
Oritavancin is in the final stages of clinical development for treatment of acute bacterial skin and skin structure infections. This drug has demonstrated potent activity against staphylococci (minimum inhibitory concentration [MIC] for which 90% of isolates are inhibited [MIC 90 ], 0.06 mg/mL), enterococci (MIC 90 , £0.008 to 0.5 mg/mL), and streptococci (MIC 90 , £0.008 to 0.12 mg/mL), including enhanced potency against vancomycin-resistant enterococci. During the clinical development of oritavancin, it was demonstrated that this molecule binds to plastic labware surfaces and that this feature was likely responsible for interlaboratory variability observed from in vitro investigations before 2006. Therefore, reference broth microdilution methods and MIC ranges for quality control strains were reestablished using media supplemented with a surfactant (polysorbate-80, 0.002%). These were followed by numerous experiments to reassess the in vitro characteristics of oritavancin; the results originating from those studies are summarized here. The oritavancin activity tested against a resistance surveillance collection of 12 367 Gram-positive clinical pathogens and resistant subsets from the United States (2008) (2009) ) is also presented, with the highest MIC among staphylococci at only 0.25 mg/mL. In vitro results for oritavancin indicate wide potential use against Gram-positive pathogens.
Oritavancin is a semisynthetic lipoglycopeptide in the final stages of clinical development for the treatment of acute bacterial skin and skin structure infections. This compound, previously known as LY333328, was initially developed by Eli Lilly during the studies of a clinical compound series derived from a naturally occurring vancomycin-like molecule, chloroeremomycin (LY264826; see manuscript by Zhanel et al in this supplement for additional structure information) [1] . Overall, chloroeremomycin possesses the same peptide core structure as vancomycin, with an additional sugar appended to the amino acid residue 6 [2, 3] . It has been shown that mono N-alkylation of chloroeremomycin generates molecules with enhanced activity against vancomycin-resistant enterococci (VRE) [4] . Among this molecule series, oritavancin was selected as a potential candidate for clinical use.
Reports published between 1996 and 2001 described the in vitro activity of oritavancin tested against Grampositive organisms; these results are summarized in Table 1 . In addition to showing the bacterial activity of oritavancin against staphylococci and streptococci, these studies reported measurable minimum inhibitory concentration (MIC) values (1-8 lg/mL) for oritavancin with testing against many VRE [4] [5] [6] [7] [8] [9] . Moreover, these older investigations described the spectrum and activity of oritavancin against a wide range of aerobic and anaerobic Gram-positive organisms that included Corynebacterium jeikeium (MIC for which 50%/90% of isolates are inhibited [MIC 50/90 ], 0.12/0.12 lg/mL), Bacillus cereus (MIC 50 , 0.5 lg/mL), Clostridium difficile (MIC 90 , 1 lg/mL), Clostridium perfringens (MIC 50/90 , 0.5/1 lg/mL), Peptostreptococcus spp. (MIC 50/90 , 0.25/ 0.5 lg/mL), Propionibacterium acnes (MIC 50/90 , 0.12/0.25 lg/mL), and Listeria spp. (MIC 50/90 , #0.03/0.06 lg/mL) [6, 7, 11, 12] .
The early reports on the enhanced in vitro activity of oritavancin against VRE were followed by investigations demonstrating bactericidal activity of this compound against these strains and also against Staphylococcus aureus [5, 13, 14] . Overall, previous time-kill curve experiments showed that oritavancin rapidly killed a methicillin-resistant S. aureus (MRSA) strain, requiring only 3 hours to decrease 3-log 10 in viable colony counts, whereas vancomycin required 24 hours to achieve the same result [5] . Oritavancin also demonstrated bactericidal activity against VanA-type VRE strains, which was concentration dependent, suggesting retention of binding affinity of oritavancin for the modified peptidoglycan or the presence of additional mechanisms of action [5, 13, 14] .
A more recent study, published in 2008, demonstrated that this molecule binds to plastic labware surfaces [15] . This previously unrecognized feature, which was not addressed in studies published before 2006 that applied older quantitative in vitro methods, caused inconsistent results (see MIC 90 values for oritavancin against staphylococci in Table 1) , and underestimated the potency of this drug. The Clinical Laboratory Standards Institute (CLSI) M100-S18 document and newer editions recommend the use of a new reference broth microdilution method that includes a surfactant (polysorbate-80 [P-80]) at 0.002% for oritavancin in vitro testing to minimize drug loss [16] .
The release of new in vitro testing conditions has prompted the reevaluation of oritavancin activity throughout a variety of in vitro microbiologic assays. The results of these studies are summarized in this report. Also presented are the oritavancin MIC data obtained when the drug was tested against a collection of Gram-positive clinical pathogens and resistant subsets collected from US hospitals as part of the SENTRY Antimicrobial Surveillance Program (2008) (2009) ).
METHODS

Literature Review
Potential microbiologic in vitro studies for review were searched for in the PubMed database using combinations of the keywords ''oritavancin'' and ''LY333328.'' Articles related to the subject of this review were retrieved and summarized where appropriate.
Bacterial Isolates
A total of 12 367 Gram-positive isolates were collected during 2008 and 2009 from 29 US hospitals located in 9 census regions Antimicrobial Susceptibility Testing
Isolates were tested for susceptibility by a reference broth microdilution procedure as described by the CLSI guidelines [17] . MIC results for oritavancin and comparators were obtained by using a validated dry-form broth microdilution panel formulation (Thermo Fisher Scientific). The dry-form formulation provides equivalent oritavancin MIC results to the revised and CLSI-approved broth microdilution method supplemented with 0.002% P-80 (M100-S21, 2011) [18] . Validation of the MIC values was assured by concurrent testing of CLSI-recommended quality control (QC) strains: Streptococcus pneumoniae American Type Culture Collection (ATCC) 49619, Enterococcus faecalis ATCC 29212, and S. aureus ATCC 29213 [18] . MIC QC results for oritavancin and comparator agents tested were within published ranges found in the CLSI M100-S21 document [18] . Interpretation of comparator MIC results was in accordance with published CLSI criteria [18] . Enterococcal isolates were clustered according to glycopeptide susceptibility. The VanA phenotype was characterized by nonsusceptibility to vancomycin (MIC, $8 lg/mL) and teicoplanin (MIC, $16 lg/mL), whereas isolates with a VanB phenotype were those nonsusceptible to vancomycin (MIC, $8 lg/mL) but susceptible to teicoplanin (MIC, #8 lg/mL), according to CLSI criteria.
RESULTS
Mode of Action
The final steps of peptidoglycan biosynthesis involve incorporation of peptidoglycan precursors into the existing cell wall by extension (transglycosylation), followed by cross-linking (transpeptidation) [19] . Glycopeptides such as vancomycin inhibit peptidoglycan biosynthesis of the bacterial cell wall by binding to the D-Ala2D-Ala of the peptidoglycan precursor, consequently inhibiting transglycosylation [20] . Recent studies have demonstrated that oritavancin has multiple mechanisms of action. This drug shares with vancomycin the ability to block transglycosylation; however, oritavancin also exerts a secondary effect on cross-linking [19, 20] . In addition, oritavancin induces membrane permeabilization along with changes in the lipid membrane integrity by collapsing transmembrane electrochemical potential and may partially inhibit RNA synthesis [21, 22] .
Bactericidal Activity and Time-Kill Kinetics
In a time-kill kinetic study, McKay et al [23] evaluated the in vitro activity of oritavancin and comparators (vancomycin, teicoplanin, daptomycin, and linezolid) against staphylococci and enterococci. In that study, oritavancin was rapidly bactericidal against vancomycin-susceptible and vancomycin-resistant S. aureus (VRSA) and enterococci. Bactericidal activity ($3 log 10 kill relative to starting inoculum) [24] was noted within 2 hours against methicillin-susceptible S. aureus (MSSA), MRSA, and VRSA at the predicted free peak (fC max ) (4 lg/mL) and trough (0.5 lg/mL) levels in plasma after a 200-mg intravenous dose in humans. Moreover, oritavancin was the only tested agent to maintain significant activity against VRSA in these experimental conditions [23] . The bactericidal activity of oritavancin was less pronounced against 2 vancomycin-intermediate S. aureus (VISA) strains compared with MSSA, MRSA, and VRSA; however, oritavancin was bactericidal at 10 hours at drug concentrations approximating fC max (16 lg/mL) for an 800-mg dose [23] . These time-kill data were consistent with the minimum bactericidal concentration (MBC) results previously obtained for oritavancin in the presence of P-80 [25] . Oritavancin demonstrated MBC 90 /MIC 90 ratios of 1, 2 and 2, respectively, against heterogeneous VISA, VISA, and VRSA, indicating bactericidal activity [25] .
With testing against vancomycin-susceptible enterococci using oritavancin concentrations approximating the fC max for an 800-mg dose, bactericidal activity was noted at 6 hours. Similarly, bactericidal activity was observed against VanA-and VanB-type enterococci within 24 hours [23] . Oritavancin was tested at in vitro concentrations similar to its fC max for a 200-mg dose in humans, and bactericidal activity was observed between 15 minutes and 3 hours against all Streptococcus pyogenes strains tested regardless of erythromycin susceptibility phenotype [26] .
Synergistic Effects
Oritavancin combined with gentamicin, moxifloxacin, or rifampin provided synergistic and bactericidal activity at 24 hours against a strain of MSSA (ATCC 29213) [27] . The addition of linezolid did not act synergistically with oritavancin against this strain. When the oritavancin plus gentamicin or oritavancin plus linezolid combinations were tested against VISA and VRSA strains, synergistic bactericidal activity was observed at the 24-hour time point [27] .
Time-Killing in Stationary Phase
It has been demonstrated that oritavancin, vancomycin, and daptomycin exhibit bactericidal activity against an exponential phase growth MSSA strain [22, 23, 27] . However, only oritavancin exhibited bactericidal activity during time-kill experiments against a stationary-phase MSSA isolate [22] . In further studies using stationary-phase inocula in nutrient-depleted media, oritavancin exerted concentration-dependent bactericidal activity against MRSA and VRSA. Moreover, bactericidal activity for oritavancin was observed at the 24-hour time point against all tested strains at fC max concentration for 200-and 800-mg doses in humans, with the exception of the 200-mg free-peak levels against a VRSA [22] . Among comparators, vancomycin showed only a modest decrease (22.2 log 10 ) in MRSA strain density, whereas daptomycin and rifampin at their fC max demonstrated bactericidal activity against the same isolate. Bactericidal activity was not evident for any of the comparators with testing against stationary-phase inocula of VRSA [22] .
Impact of Serum Albumin
Studies were performed to address the influence of biologic fluids such as human serum on the in vitro activity of oritavancin. Those studies demonstrated that 4% human serum [28] . Moreover, the oritavancin results obtained by time-kill experiments against MSSA, MRSA, and VRSA were similar in the presence and absence of HSA [28] . When oritavancin was tested against enterococcal strains in the presence of HSA, the MIC values increased up to 8-fold. Among the compounds tested in time-kill experiments with HSA, oritavancin was the only agent to demonstrate bactericidal activity against a vancomycin-susceptible E. faecalis strain at the expected in vivo peak levels (32 lg/mL total drug) for a 200-mg dose. In addition, bacteriostatic activity was observed for oritavancin in the presence of HSA against VanA and VanB VRE at the total peak concentration. Linezolid also demonstrated bacteriostatic activity against some VanA-and VanB-type strains [29] .
Impact of Varying Testing Conditions on Oritavancin MIC Values
Reports before 2006 described oritavancin MIC results that varied when different testing protocols and growth media [4] . MIC variations among earlier oritavancin reports indicated that method, media supplements, and testing conditions could influence susceptibility testing results (Table 1) . During development of in vitro testing methods for dalbavancin, a pivotal study described the application of P-80 [30] . P-80 acts as a nonionic surfactant and emulsifier and has been widely used in commercially prepared susceptibility panels as a dispersion agent for many compounds. This supplement was later determined to be essential for accurate dalbavancin MIC determinations, initiating a modification in the broth microdilution testing that would soon be adopted by other pharmaceutical companies when developing similar investigational glycopeptidelike compounds [31, 32] .
Subsequently, Arhin et al [15] investigated the effects of P-80 during antimicrobial susceptibility testing of oritavancin, and MIC values were evaluated using cation-adjusted MHB with and without this supplement. The addition of P-80 provided more reproducible results and a remarkable decrease in oritavancin MIC values against S. aureus (32-fold) and E. faecalis (16-fold) ATCC control strains compared with those obtained without supplementation. In contrast, the oritavancin MIC values were minimally affected by P-80 with testing against the S. pneumoniae ATCC 49619, because constituents present in the lysed horse blood act as surfactant. These study findings concluded that P-80 supplementation is required during drug dissolution, dilution, and assay for accurate assessment of the in vitro oritavancin MIC; a revised broth microdilution method was consequently established [31] . The wide acceptance of a new procedure for the in vitro MIC testing of oritavancin led to reevaluation of MIC QC ranges for reference strains of S. aureus, E. faecalis, and S. pneumoniae [31] . The addition of P-80 reduced the oritavancin MIC results considerably against the reference staphylococcal and enterococcal strains. Thus, the updated MIC QC ranges differed greatly from those previously published in the CLSI M100-S17 document [33] . Also determined were the impact of varying testing conditions such as incubation time, incubation in carbon dioxide, pH, presence of calcium ions, panel stability, and inoculum size. Broth microdilution MIC determinations were not affected by any of these conditions except inoculum concentrations of 10 7 colony-forming units/mL for the S. aureus and E. faecalis ATCC strains [31] .
Baseline and Contemporary Oritavancin In Vitro MIC Results
Reassessment of Baseline MIC Results
After recognition of the requirement of P-80 supplementation for oritavancin susceptibility testing and the establishment of a new broth microdilution method with MIC QC ranges [16] , it became apparent that reports before 2006 [5-9, 13, 14] underestimated the in vitro potency of the drug. Therefore, studies were initiated to reestablish the baseline activity of oritavancin tested against contemporary Gram-positive clinical organisms [10, 15] . These studies showed decreases in oritavancin MIC values with testing against clinical staphylococcal and enterococcal isolates, decreases similar to those described for ATCC QC strains [31] . The MIC 90 values for E. faecalis, E. faecium, and coagulase-negative staphylococci (CoNS) decreased 16-fold when compared with those obtained with no P-80 supplementation, whereas the MIC 90 result for oritavancin against S. aureus decreased 32-fold in the presence of P-80. P-80 supplement had little effect on the oritavancin MIC values for clinical isolates of streptococci [15] . Table 1 aureus and CoNS, which inhibited all isolates at #0.25 lg/mL (Table 2) . Moreover, oritavancin MIC 90 results were not adversely affected by susceptibility phenotypes, such as methicillin resistance, or in testing against isolates with decreased susceptibility for vancomycin (MIC, 2 lg/mL) ( Overall, oritavancin showed pronounced activity against streptococci, inhibiting all S. pneumoniae, viridians group streptococci, and b-hemolytic streptococci at #0.06, #0.25 and #0.5 lg/mL, respectively (Table 2) (Table 3) . Similarly, oritavancin (MIC 50/90 , 0.03/0.06 lg/mL) was 8-fold more active than daptomycin (MIC 50/90 , 0.25/0.5 lg/mL), 16-32-fold more active than linezolid (MIC 50/90 , 1/1 lg/mL) and 32-64-fold more active than vancomycin (MIC 50/90 , 2/2 lg/mL) when tested against a US collection of CoNS (Table 3) . Other comparator agents displayed limited activity when tested against MRSA or CoNS except tetracycline and trimethoprim-sulfamethoxazole, which showed higher level coverage when tested against MRSA strains ($94.7% susceptible by CLSI criteria) [18] .
When tested against vancomycin-susceptible E. faecalis, oritavancin (MIC 50/90 , 0.015/0.03 lg/mL) had a MIC 90 value 64-fold lower than ampicillin (MIC 50/90 , #1/2 lg/mL), vancomycin (MIC 50/90 , 1/2 lg/mL), daptomycin (MIC 50/90 , 1/2 lg/mL), and linezolid (MIC 50/90 , 1/2 lg/mL) ( streptococci (Table 5) . Oritavancin (MIC 50/90 , 0.03/0.12 lg/mL) and penicillin (MIC 50/90 , 0.03/0.06 lg/mL) were the most active compounds against b-hemolytic streptococci (Table 5) .
DISCUSSION
Oritavancin has clearly demonstrated promising antimicrobial activity, which includes in vitro activity against VRE [4] [5] [6] [7] [8] [9] . As described above, the oritavancin MIC results reported before 2006 showed significant interlaboratory variability, later attributed to lack of standard protocols addressing the propensity of oritavancin to bind to plastic labware surfaces. Since the recognition of this testing characteristic and establishment of a revised reference broth microdilution method, the in vitro antimicrobial activity of oritavancin has been reassessed and standardized [10, 15, 31] . Previous in vitro studies (1996) (1997) (1998) (1999) (2000) (2001) (Table 1 ) demonstrated oritavancin MIC 90 results of 0.5-8 lg/mL when oritavancin was tested against staphylococci. However, baseline MIC 90 values between 0.12 and 0.25 lg/mL were later reported [10, 15] . Similarly, MIC 90 values reported for oritavancin tested in the absence of P-80 against enterococci were 0.25-4 lg/mL (Table 1) , whereas the new method provided oritavancin with MIC 90 ranges of 0.03 and 1 lg/mL [10, 15] . The oritavancin MIC results for streptococci were less affected owing to the presence of lysed horse blood.
Overall, the oritavancin activity reported before 2006 can be described as comparable to that of vancomycin with distinguishing potency against VRE. The development of a new, more accurate reference broth microdilution method has altered the understanding of oritavancin activity, because the oritavancin MIC values for staphylococci and enterococci decrease, on average, by 16-32-fold. Therefore, it is important to emphasize that modifications in the reference method for oritavancin are necessary to maintain the intended concentration of oritavancin during in vitro testing and consequently to obtain more accurate and reproducible results. These changes in method do not necessarily imply greater in vivo efficacy for oritavancin.
Another distinguishing characteristic of oritavancin is its antimicrobial activity against stationary-phase bacteria when compared with vancomycin and compounds in other chemical classes, including lipopeptides, oxazolidinones, and ansamycins [22] . The finding of oritavancin bactericidal activity against stationary-phase cells corroborates the presence of additional mechanisms of action [19] [20] [21] [22] 34] . The effects of oritavancin on membrane integrity probably play an important role on its bactericidal activity in stationary-phase systems. In contrast, the absence of vancomycin activity in these systems, where cell growth is limited, correlates with a single mode of action and the need for cell wall division to empower vancomycin with bactericidal activity. However, membrane-perturbing agents, such as oritavancin, remain bactericidal against cells in limitedgrowth states [22, 34] .
Finally, this report describes potent oritavancin activity that was equivalent to or greater than that for comparator antimicrobial agents with testing against numerous species of contemporary organisms collected from US hospitals (Tables 225). This enhanced bacterial activity is probably due to a combination of modes of action, which give oritavancin attractive in vitro characteristics that distinguish it from other glycopeptidelike compounds. Phase 3 clinical trials with an optimized dosing strategy [35] [36] [37] [38] will assess the efficacy and safety of oritavancin therapy against Gram-positive infections and determine whether the more recently recognized and characterized in vitro features translate into favorable clinical outcomes. 
